

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/535,378
				Filing Date	November 21, 2003 (I.A.)
				First Named Inventor	Mark H. Kaplan
				Art Unit	to be assigned
				Examiner Name	to be assigned
Sheet	2	of	3	Attorney Docket Number	50425/223

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SC/	2	ANDREOLI J.M. et al. "The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis"; Nucleic Acids Research, 1997, Vol. 25, No. 21, pp 4287-95.	
/SC/	3	BARNES D.M. et al. "Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?" European Journal of Cancer, 1992, Vol. 28, No. 2/3, pp 644-48.	
/SC/	4	CHANG C-H. et al. "ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis"; Oncogene, 1997, Vol. 14, pp 1617-22.	
/SC/	5	CHANG C-H. et al. "Exon 4-encoded acidic domain in the epithelium restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP)"; Oncogene, 1999, Vol. 18, pp 3682-95.	
/SC/	6	CHANG J. et al. "Over-expression of ERT (ESX/ESE/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells"; Oncogene, 2000, Vol. 19, pp 151-54.	
/SC/	7	KIM J-H. et al. "Activation of the Murine Type II Transforming Growth Factor-Beta Receptor Gene" Journal of Biological Chemistry, 2002, Vol. 277, No. 20, pp 17520-30.	
/SC/	8	MA Y. et al. "Microarray analysis uncovers retinoid targets in human bronchial epithelial cells"; Oncogene, 2003, Vol. 22, pp 4924-32.	
/SC/	9	OETTGEN P. et al. "The Novel Epithelial-Specific Ets Transcription Factor Gene ESX Maps to Human Chromosome 1q32.1"; Genomics, 1997, Vol. 45, pp 456-57.	
/SC/	10	OETTGEN P. et al. "Isolation and Characterization of a Novel Epithelium-Specific Transcription Factor, ESE-1, a Member of the ets Family"; Molecular and Cellular Biology, 1997, Vol. 17, No. 8, pp 4419-33.	
/SC/	11	OETTGEN P. et al. "Genomic Organization of the Human ELF3 (ESE-1/ESX) Gene, A Member of the Ets Transcription Factor Family, and Identification of a Functional Promoter"; Genomics, 1999, Vol. 55, No. 3, pp 358-62.	

Examiner Signature	/Suryaprabha Chunduru/	Date Considered	06/25/2007
--------------------	------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/535,378
				Filing Date	November 21, 2003 (I.A.)
				First Named Inventor	Mark H. Kaplan
				Art Unit	to be assigned
				Examiner Name	to be assigned
Sheet	3	of	3	Attorney Docket Number	50425/223

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SC/	12	RAYNOR M. et al. "Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells"; BMC Cancer, 2002, Vol. 2, p. 14 et seq.	
/SC/	13	ROY-ENGEL A.M. et al. "Alu Insertion Polymorphisms for the Study of Human Genomic Diversity"; Genetics, 2001, Vol. 159, pp 279-90.	
/SC/	14	TANG Y. et al. "ELF a Beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene"; Oncogene, 2002, Vol. 21, pp 5255-67.	
/SC/	15	TYMMS M.J. et al. "A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer"; Oncogene, 1997, Vol. 15, pp 2449-62.	

Examiner Signature	/Suryaprabha Chunduru/	Date Considered	06/25/2007
-----------------------	------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.